Skip to content
Low-Dose Pfizer-BioNTech Vaccine Fails in Trial in Children 2 to 5 Years of Age

 | Breaking News Updates

Low-Dose Pfizer-BioNTech Vaccine Fails in Trial in Children 2 to 5 Years of Age

| Latest News Headlines | Google News

A low dose of Pfizer-BioNTech coronavirus vaccine failed to produce an adequate response in children aged two to five years.

Businesses announcement the results of critical trials underway on Friday and said that after testing children 6 months to 5 years old with atenth of the adult dose, children between 6 months and 2 years old produced an immune response similar to that of people 16 to 25 years old after two doses, but children between 2 and 5 years old did not.

A syringe is prepared with the Pfizer COVID-19 vaccine at a clinic at the Norristown Public Health Center in Norristown, Pa. On Tuesday, December 7, 2021. (AP Photo / Matt Rourke)

BIDEN WARNS OF “WINTER OF SERIOUS ILLNESS AND DEATH” FOR UNVACCINATED

“The companies will modify the clinical study evaluating the safety, tolerability and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to less than 5 years of age,” the statement said. “The study will now include the evaluation of a third dose of 3 µg at least two months after the second dose of the two-dose series to provide high levels of protection in this young age group.”

The companies said if the three-dose study is successful, they plan to seek emergency clearance in the first half of 2022.

Low-Dose Pfizer-BioNTech Vaccine Fails in Trial in Children 2 to 5 Years of Age

 | Breaking News Updates

Germaine T. Leftwich, 67, receives a Pfizer covid-19 vaccine booster from Dr. Tiffany Taliaferro at the Capitol Hill Safeway in Washington, DC on Monday, October 4, 2021.
(Tom Williams / CQ-Roll Call, Inc via Getty Images)

BIDEN’S HOLIDAY PLANS DO NOT CHANGE DUE TO COVID-19: PSAKI

A children’s version of Pfizer’s vaccine is already available for children aged 5 to 11, or one-third the dose given to everyone aged 12 and over.

No security issues were detected in the study, the companies said.

Pfizer’s vaccine research chief Kathrin Jansen cited other data showing that a booster for people 16 and older restores strong protection, a jump in immunity that scientists say will help also to push back the new variant of the omicron.

Low-Dose Pfizer-BioNTech Vaccine Fails in Trial in Children 2 to 5 Years of Age

 | Breaking News Updates

This image provided by Pfizer shows its COVID-19 pill. Drugmaker Pfizer said on Tuesday, November 16, 2021 that it was submitting its experimental pill for U.S. clearance, setting the stage for a likely launch in the coming weeks. (Pfizer via AP)
(Pfizer via AP)

CLICK HERE TO GET THE FOX NEWS APP

The companies are also preparing to test a booster for children aged 5 to 11, who have just received their vaccines in two doses. And they’re testing different dose options for teen boosters.

Jansen said if the additional pediatric tests were successful, “we would have a consistent approach to the three-dose vaccine for all ages.”

Associated Press contributed to this report

Latest News Headlines Fox news Low-Dose Pfizer-BioNTech Vaccine Fails in Trial in Children 2 to 5 Years of Age

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.